Evaluation and Management of Late Effects of Cancer Treatment

Gleeson, Helena; Shalet, Stephen M

doi:10.1002/9781444316728.ch8

Cited by 2 publications

(2 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 As the risk of relapse is greatest within the first 2 years from primary treatment, it is common to delay initiation of rhGH therapy for 2 years. 16…”

Section: Recombinant Human Growth Hormone After Brain Tumorsmentioning

confidence: 99%

Relapse and Metastasis of Atypical Teratoid/Rhabdoid Tumor in a Boy with Neurofibromatosis Type 1 Treated with Recombinant Human Growth Hormone

et al. 2015

View full text Add to dashboard Cite

Even though no increased recurrence rate seems to be reported in patients with brain tumors receiving recombinant human growth hormone (rhGH) replacement, in some patients multiple risk factors could put at higher risk for recurrence. In such cases, the decision to start rhGH therapy should be very cautious. A boy with neurofibromatosis type 1 developed an atypical teratoid/rhabdoid tumor (AT/RT) of right cerebellum, treated with surgery, radiotherapy, and chemotherapy. After 3 years of remission, he started rhGH for growth hormone deficiency, having a negative magnetic resonance imaging (MRI) scan. Ten weeks after starting therapy, the boy became symptomatic and MRI showed relapse of AT/RT in the right cerebellum and a new lesion in the brainstem. The boy died of progressive disease. In this case, the connection between AT/RT recurrence and the beginning of rhGH therapy, with a negative pretreatment MRI, cannot be excluded. Additional caution should be used for rhGH in patients with multiple risk factors.

show abstract

“…15 As the risk of relapse is greatest within the first 2 years from primary treatment, it is common to delay initiation of rhGH therapy for 2 years. 16…”

Section: Recombinant Human Growth Hormone After Brain Tumorsmentioning

confidence: 99%

Relapse and Metastasis of Atypical Teratoid/Rhabdoid Tumor in a Boy with Neurofibromatosis Type 1 Treated with Recombinant Human Growth Hormone

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Children exposed to cranial irradiation are more prone to develop central precocious puberty, presumably due to disruptive effects on the inhibitory pathways on the hypothalamus (3).While girls are more susceptible than boys at lower doses of radiation (18-24 Gy), both boys and girls are similarly prone to early onset puberty at higher doses (30-50 Gy) (6). Early puberty may be followed several years later by gonadotropin deficiency.…”

Section: Puberty and Gonadal And Reproductive Functionmentioning

confidence: 99%

Endocrine late effects in paediatric cancer survivors

Seneviratne

Silva

2012

Sri Lanka J. Diabetes Endocrinol. Metab.

View full text Add to dashboard Cite

Improved survival following childhood malignancy has led to increased recognition of a multitude of late adverse effects in long term survivors, which affect their quality of life. Endocrine complications are among the commonest late effects seen and include dysfunction of the hypothalamo pituitary axis leading to impaired growth, abnormal puberty or hypopituitarism, gonadal dysfunction and infertility, thyroid gland dysfunction and neoplasms, obesity, impaired glucose homeostasis and abnormal bone development. Long term follow up is needed for early recognition and timely intervention to minimise the effects of these complications.

show abstract

Evaluation and Management of Late Effects of Cancer Treatment

Cited by 2 publications

References 202 publications

Relapse and Metastasis of Atypical Teratoid/Rhabdoid Tumor in a Boy with Neurofibromatosis Type 1 Treated with Recombinant Human Growth Hormone

Relapse and Metastasis of Atypical Teratoid/Rhabdoid Tumor in a Boy with Neurofibromatosis Type 1 Treated with Recombinant Human Growth Hormone

Endocrine late effects in paediatric cancer survivors

Contact Info

Product

Resources

About